Results 151 to 160 of about 5,926 (192)

Talazoparib in Patients with a Germline BRCA-Mutated Advanced Breast Cancer: Detailed Safety Analyses from the Phase III EMBRACA Trial [PDF]

Oncologist, 2020
BACKGROUND:In the EMBRACA phase III study (NCT01945775), talazoparib was associated with a significantly prolonged progression-free survival (PFS) compared with physician's choice of chemotherapy (PCT) in germline BRCA1/2-mutated HER2-negative advanced ...
Sara A Hurvitz, Anthony Gonçalves, Hope S Rugo   +2 more
exaly   +2 more sources

Talazoparib in Patients with Advanced Breast Cancer and a Germline BRCA Mutation [PDF]

New England Journal of Medicine, 2018
BACKGROUND: The poly(adenosine diphosphate-ribose) inhibitor talazoparib has shown antitumor activity in patients with advanced breast cancer and germline mutations in BRCA1 and BRCA2 ( BRCA1/2).
Jennifer K Litton, Hope S Rugo, Sara A Hurvitz   +2 more
exaly   +2 more sources

Talazoparib versus chemotherapy in patients with germline BRCA1/2-mutated HER2-negative advanced breast cancer: final overall survival results from the EMBRACA trial

Annals of Oncology, 2020
Background: In EMBRACA, talazoparib prolonged progression-free survival versus chemotherapy (hazard ratio [HR] 0.542 [95% confidence interval (CI) 0.413-0.711]; P < 0.0001) and improved patient-reported outcomes (PRO) in germline BRCA1/2 (gBRCA1/2 ...
S Diab, Natasha Woodward, A Goodwin
exaly   +2 more sources

Some of the next articles are maybe not open access.

Related searches:

Talazoparib (Talzenna) for Prostate Cancer

The Medical Letter on Drugs and Therapeutics, 2023
The oral poly(ADP-ribose) polymerase (PARP) inhibitor talazoparib (Talzenna – Pfizer) has been approved by the FDA for use in combination with the androgen receptor blocker enzalutamide (Xtandi) for treatment of adults with homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer (mCRPC).
openaire   +2 more sources

Talazoparib Does Not Interact with ABCB1 Transporter or Cytochrome P450s, but Modulates Multidrug Resistance Mediated by ABCC1 and ABCG2: An in Vitro and Ex Vivo Study

International Journal of Molecular Sciences, 2022
Talazoparib (Talzenna) is a novel poly (adenosine diphosphate-ribose) polymerase (PARP) inhibitor that is clinically used for the therapy of breast cancer.
Ziba Sabet, Dimitrios Vagiannis, Youssif Budagaga   +2 more
exaly   +2 more sources

Population Pharmacokinetics of Talazoparib in Patients With Advanced Cancer

The Journal of Clinical Pharmacology, 2019
AbstractPoly(ADP‐ribose) polymerase (PARP) inhibitors have been developed to treat cancers associated with somatic BRCA mutations and germline genetic aberrations involved in the DNA damage response. The efficacy, tolerability, and pharmacokinetic/pharmacodynamic (PK/PD) profile of talazoparib, a potent small‐molecule PARP inhibitor, was established in
Yanke, Yu, Chandrasekar, Durairaj, Haihong, Shi, Diane D, Wang   +3 more
openaire   +2 more sources

Talazoparib for the treatment of prostate cancer

Expert Opinion on Pharmacotherapy
Around 25% of patients with advanced prostate cancer harbor alterations in the homologous recombination/DNA damage repair (HRR) pathway. Inhibiting poly (ADP-ribose) polymerase (PARP) in these patients leads to synthetic lethality, making PARP inhibitors (PARPi), including talazoparib, a promising treatment for metastatic castration-resistant prostate ...
Arshit, Narang, Chadi, Hage Chehade, Zeynep Irem, Ozay, Blake, Nordblad, Umang, Swami, Neeraj, Agarwal   +5 more
openaire   +2 more sources

Abstract OT2-03-04: A trial of induction Talazoparib followed by a combination of Talazoparib and Avelumab in advanced breast cancer: The TALAVE study

Cancer Research, 2020
Abstract Background: Patients with advanced breast cancer (ABC) have recently gained access to promising new therapies, including PARP inhibitors (PARPi) and immunotherapy. However, not all patients benefit from these approaches, with response rates highest in patients characterized by a particular biomarker (ie BRCA1/2 mutation or PD-L1
Arielle L Heeke, Michael Pishvaian, Hongkun Wang, Adam Cohen, Jeffrey Schlom, Renee Donahue, Caroline Jochems, Margaret Gatti-Mays, Paula Pohlmann, Antoinette Tan, Claudine Isaacs, Filipa Lynce   +11 more
openaire   +1 more source

Detection and analysis of the safety profile of talazoparib based on FAERS database

Expert Opinion on Drug Safety
Talazoparib was approved for the treatment of breast cancer. However, the safety of talazoparib in a large population sample over an extended period remained uncertain. The objective of this study is to offer guidance for the secure utilization of talazoparib in clinical settings.
Peiyan Liu, Yang Li
exaly   +3 more sources

Proteomic analysis of talazoparib resistance in triple‐negative breast cancer cells

Journal of Biochemical and Molecular Toxicology, 2020
AbstractTalazoparib (TAL) has been effectively used for the treatment of gBRCA1/2‐mutated HER2‐negative metastatic breast cancer. However, acquired resistance to TAL remains a major challenge that impedes the clinical success of TAL treatment. Therefore, elucidation of proteins and pathways that contribute to or are affected by the TAL resistance is ...
Gamze Guney Eskiler, Sevinc Yanar, Gurler Akpinar, Murat Kasap   +3 more
openaire   +3 more sources